Clinical Trials
8 trialsNCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05230186 2022-02-09
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
TScan Therapeutics, Inc.
Unknown
NCT04142931 2021-03-24
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Sheba Medical Center
Phase 1 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT04107142 2019-09-27
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
CytoMed Therapeutics Pte Ltd
Phase 1 Unknown
NCT02950064 2019-01-14
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
Placon Therapeutics
Phase 1 Unknown
NCT03076372 2018-02-27
A Study Evaluating MM-310 in Patients With Solid Tumors
Merrimack Pharmaceuticals
Phase 1 Unknown